The United Kingdom and the United States have finalized a significant bilateral deal that will guarantee no import taxes on British medicine exports going into the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these crucial products will be held at zero for a period of three years.
This development is in response to previous statements to hike duties on patented pharmaceutical products, with figures discussed up to double the cost.
"This deal with the United Kingdom strengthens the international landscape for innovative medicines and introduces long-overdue fairness to American-British pharmaceutical trade," a release noted.
Economic Significance
Drugs constitute one of the UK's biggest export categories to the America, which is easily the biggest destination for major UK drugmakers.
Statistics show that in the one-year period to the end of last September, the UK shipped drugs valued at over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that span.
"This agreement safeguards jobs, stimulates investment and facilitates the UK to emerge as a international leader for medical research," a government official commented.
Detailed NHS Changes
The deal includes several notable pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to raise total public funding on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be capped at 15%. Previously, refunds were more than 20%.
Recent Tensions
This agreement takes place against a protracted dispute between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were heightened by assertions that US customers were paying several times more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward US facilities.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the past decade.
